SCHEMBL24364916

SCHEMBL24364916

CN1CCC(c2nc3cc(Br)ccc3s2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 8/20 0.49
DCUN1D1 Q96GG9 8/20 0.49
LMNA P02545 3/20 0.49
TP53 P04637 3/20 0.49
MAPT P10636 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 2/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
GRM2 Q14416 1/20 0.43
GAA P10253 1/20 0.41
DYRK1A Q13627 1/20 0.41
APP P05067 1/20 0.41
ALOX12 P18054 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30470618 1.00 UBE2M (0.49) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL25911232 0.92 UBE2M (0.45) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL30470891 0.92 UBE2M (0.45) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL30886942 0.89 APP (0.52) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL29210777 0.89 APP (0.52) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL16132861 0.87 NPC1 (0.52) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL23010591 0.84 UBE2M (0.50) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL32688979 0.84 UBE2M (0.41) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL25923036 0.84 UBE2M (0.41) UBE2MDCUN1D1LMNATP53MAPT
SCHEMBL30753156 0.83 NPC1 (0.65) UBE2MDCUN1D1LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 UBE2M 2694/4885DCUN1D1 2567/4885LMNA 1976/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 UBE2M 2694/4885DCUN1D1 2567/4885LMNA 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.